Abbott India Limited Asset Resilience Ratio
Abbott India Limited asset resilience ratio. Abbott India Limited (ABBOTINDIA) has an Asset Resilience Ratio of 53.22% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Abbott India Limited to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Abbott India Limited (2005–2025)
Asset resilience ratio of Abbott India Limited from 2005 to 2025. This chart shows how Abbott India Limited's Asset Resilience Ratio has changed over time. Read Abbott India Limited (ABBOTINDIA) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Abbott India Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ABBOTINDIA asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs12.79 Billion | 22.46% |
| Short-term Investments | Rs17.51 Billion | 30.75% |
| Total Liquid Assets | Rs30.30 Billion | 53.22% |
Asset Resilience Insights
- Very High Liquidity: Abbott India Limited maintains exceptional liquid asset reserves at 53.22% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Abbott India Limited Industry Peers by Asset Resilience Ratio
Compare Abbott India Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Abbott India Limited Asset Resilience Ratio by Year (2005–2025)
Abbott India Limited asset resilience ratio by year from 2005 to 2025. The table below shows the annual Asset Resilience Ratio data for Abbott India Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 51.26% | Rs30.33 Billion ≈ $328.01 Million |
Rs59.17 Billion ≈ $639.93 Million |
+12.66pp |
| 2024-03-31 | 38.59% | Rs20.04 Billion ≈ $216.75 Million |
Rs51.93 Billion ≈ $561.66 Million |
-2.24pp |
| 2023-03-31 | 40.83% | Rs18.60 Billion ≈ $201.18 Million |
Rs45.56 Billion ≈ $492.66 Million |
-22.31pp |
| 2022-03-31 | 63.15% | Rs26.67 Billion ≈ $288.48 Million |
Rs42.24 Billion ≈ $456.82 Million |
+2.00pp |
| 2020-03-31 | 61.14% | Rs21.69 Billion ≈ $234.53 Million |
Rs35.47 Billion ≈ $383.58 Million |
+7.69pp |
| 2019-03-31 | 53.46% | Rs15.72 Billion ≈ $170.01 Million |
Rs29.41 Billion ≈ $318.05 Million |
+12.59pp |
| 2018-03-31 | 40.86% | Rs9.87 Billion ≈ $106.78 Million |
Rs24.16 Billion ≈ $261.30 Million |
-11.65pp |
| 2017-03-31 | 52.51% | Rs10.85 Billion ≈ $117.32 Million |
Rs20.66 Billion ≈ $223.41 Million |
+9.48pp |
| 2016-03-31 | 43.03% | Rs6.96 Billion ≈ $75.23 Million |
Rs16.17 Billion ≈ $174.82 Million |
-0.04pp |
| 2015-03-31 | 43.07% | Rs5.92 Billion ≈ $63.99 Million |
Rs13.74 Billion ≈ $148.55 Million |
+19.96pp |
| 2013-03-31 | 23.11% | Rs2.10 Billion ≈ $22.67 Million |
Rs9.07 Billion ≈ $98.10 Million |
+4.93pp |
| 2012-03-31 | 18.18% | Rs1.46 Billion ≈ $15.74 Million |
Rs8.00 Billion ≈ $86.54 Million |
+13.97pp |
| 2011-03-31 | 4.22% | Rs192.81 Million ≈ $2.09 Million |
Rs4.57 Billion ≈ $49.46 Million |
+0.06pp |
| 2010-03-31 | 4.15% | Rs161.22 Million ≈ $1.74 Million |
Rs3.88 Billion ≈ $41.97 Million |
+0.97pp |
| 2009-03-31 | 3.19% | Rs111.80 Million ≈ $1.21 Million |
Rs3.51 Billion ≈ $37.91 Million |
-0.05pp |
| 2008-03-31 | 3.24% | Rs107.00 Million ≈ $1.16 Million |
Rs3.30 Billion ≈ $35.73 Million |
-0.53pp |
| 2007-03-31 | 3.77% | Rs128.30 Million ≈ $1.39 Million |
Rs3.40 Billion ≈ $36.82 Million |
-0.20pp |
| 2006-03-31 | 3.97% | Rs123.30 Million ≈ $1.33 Million |
Rs3.10 Billion ≈ $33.57 Million |
+1.77pp |
| 2005-03-31 | 2.21% | Rs68.90 Million ≈ $745.13K |
Rs3.12 Billion ≈ $33.75 Million |
-- |
About Abbott India Limited
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, … Read more